ArticleScience (New York, N.Y.)2021
A broadly protective antibody that targets the flavivirus NS1 protein.
Article in Science (New York, N.Y.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 78 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
78 citing papers in PubMed, 118 citations in OpenAlex.
- Vaccine-induced T cell responses control Orthoflavivirus challenge infection without neutralizing antibodies in humans.Nature microbiology · 2025Trial
- Differential properties of NS1 glycoproteins in West Nile and Usutu viruses.Emerging microbes & infections · 2026Article
- Article
- Emerging viral infections: role of flavivirus NS1-mediated rewiring of PRR signaling.European cytokine network · 2026Review
- CLEC5A/TLR2 bispecific antibody suppresses dengue virus-induced pro-inflammatory cytokines production from macrophages.Journal of biomedical science · 2026Article
- A secretion-deficient DENV1 DNA vaccine induces durable immunity and confers protection against DENV2.Zoological research · 2026Article
- Secretory NS1' protein of orthoflavivirus promotes viral transmission to mosquitoes by suppressing the RNAi pathway.Science China. Life sciences · 2026Article
- Dynamic structures of dengue virus serotype 2 secreted NS1 and their interactions with heparan sulfate.Nature communications · 2026Article
- Review
- Consensus-based computational mapping of NS1 antigenic determinants in dengue and Zika viruses to improve diagnostic specificity.BMC infectious diseases · 2026Article
- IgA-driven neutrophil activation underlies severe dengue disease after primary Zika virus infection in humans.Nature immunology · 2026Article
- EMoMiS: A pipeline for epitope-based molecular mimicry search in protein structures with potential applications to SARS-CoV-2.Computational and structural biotechnology journal · 2026Article
- Antibodies Against SARS-CoV-2 Nucleocapsid Protein Possess Autoimmune Properties.Antibodies (Basel, Switzerland) · 2025Article
- Dengue and severe dengue.Clinical microbiology reviews · 2025Review
- Flavivirus NS1-triggered endothelial dysfunction promotes virus dissemination.PLoS pathogens · 2025Article
- Dengue Virus NS1 Binds Ephrin B1 to Trigger Endothelial Dysfunction.bioRxiv : the preprint server for biology · 2025Article
- Dengue virus NS1 protein does not activate TLR4 and has a modest effect on endothelial monolayer integrity compared to TNF.PLoS pathogens · 2025Article
- Endothelial leak and knowledge gaps: yellow fever virus non-structural protein 1 and the antibodies that bind it.Virology journal · 2025Review
- Review
- Zika virus vaccines and monoclonal antibodies: a priority agenda for research and development.The Lancet. Infectious diseases · 2025Review
18 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
25 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There are no approved flaviviral therapies and the development of vaccines against flaviruses has the potential of being undermined by antibody-dependent enhancement (ADE). The flavivirus nonstructural protein 1 (NS1) is a promising vaccine antigen with low ADE risk but has yet to be explored as a broad-spectrum therapeutic antibody target. Here, we provide the structural basis of NS1 antibody cross-reactivity through cocrystallization of the antibody 1G5.3 with NS1 proteins from dengue and Zika viruses. The 1G5.3 antibody blocks multi-flavivirus NS1-mediated cell permeability in disease-relevant cell lines, and therapeutic application of 1G5.3 reduces viremia and improves survival in dengue, Zika, and West Nile virus murine models. Finally, we demonstrate that 1G5.3 protection is independent of effector function, identifying the 1G5.3 epitope as a key site for broad-spectrum antiviral development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.